antagonists (ticagrelor or prasugrel) for the secondary prevention of cardiovascular disease.
Introduction
Acute coronary syndrome (ACS) is a substantial cause of morbidity and mortality, accounting for 75000 hospitalisations in Australia in 2010. Just over 1/3 of these hospitalisations were for recurrent events, accounting for nearly one half the overall economic cost of ACS and a 20% absolute mortality rate -double that of those suffering their first event.
1 Individuals who survive an ACS therefore stand to derive substantial absolute benefits from pharmacological interventions that reduce recurrent cardiovascular events, highlighting the importance and cost-effectiveness of secondary prevention. Despite national guidelines, 2 currently only a half to two thirds of eligible patients in Australia receive at least four out of five guideline based pharmacotherapies on hospital discharge following a diagnosis of ACS. 
Fibrates
Fibric acid derivatives typically reduce triglyceride concentrations by 30-50% and increase HDL cholesterol concentrations by up to 10%. A meta-analysis by Lee et al. of randomised controlled trials investigating fibrate therapy found that compared to placebo, fibrates given to secondary prevention patients with both hypertriglyceridaemia (defined as triglycerides > 2.3mmol/L or nearest equivalent) and low HDL-C (defined as HDL-C < 1.03mmol/L or nearest equivalent) reduced the risk of cardiovascular events by 28%, noting there were no significant mortality reductions observed. 4 In patients with neither lipid abnormality in the overall population (patients with CHD or diabetes) there was no effect of fibrates on cardiovascular events.
In recent years fibrates used in patients with diabetes have also been shown to reduce the progression of retinopathy (37%), need for amputations (36%), and progression of nephropathy (with possible improvements), effects which are independent of baseline lipid profiles.
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Fenofibrate is the only drug of this class safely recommended for concomitant administration with statins, due to increased risks of myotoxicity and rhabdomyolysis with other fibrates. The most frequently reported adverse effects are gastrointestinal, while there are with rare risks of pancreatitis (0.3%) and pulmonary embolism (0.4%). 6 Current evidence indicates fibrates are effective in the prevention of cardiovascular events without a clear mortality reduction, but benefits appear limited to patients with residual dyslipidaemia. There are additional pronounced microvascular benefits for people with diabetes.
Fish oils
Research arising from long term population studies linking high seafood intake with lower rates of cardiovascular events and mortality led to the isolation of omega-3 polyunsaturated fatty acids as the most likely active constituent. However randomised trials examining cardiovascular outcomes with fish oils have produced conflicting evidence. A systematic review in 2012, including twenty trials and data from around 63000 trial participants, found fish oils had no effect on the primary composite cardiovascular outcome. 7 Amongst the thirteen trials reporting on cardiovascular mortality, there was a significant 14% reduction in risk overall, noting significant trial heterogeneity (I triglyceride levels (greater benefits with higher baseline triglyceride levels); age of trial participants (greater benefits in younger patients); and the presence of hypertension or diabetes (greater benefits in patients without these comorbidities). 7 Several trials in this meta-analysis had control groups which were on a Mediterranean diet, used olive oil as a control or had a fish rich diet, all of which could have masked the benefits of omega-3 supplementation with their own cardio-protective effects. A linear response to fish oil intake and CVD protection has never been established, suggesting supplementation beyond a certain level of intake may not confer additional benefits. 8 The commonest side effect of oral fish oil use is gastrointestinal upset (fishy aftertaste, reflux and diarrhoea), although this can often be lessened with enteric coating. Limited evidence exists regarding serious adverse effects of omega-3 fatty acids. No effect on cancer incidence has been reported in meta-analyses of eight randomised studies from a systematic review. 7 Currently the evidence base for the use of fish oils to reduce cardiovascular or mortality endpoints is limited, and general conclusions are that the available evidence is not adequate to strongly support the use or cessation of omega-3 fatty acids in the secondary prevention of CVD. 7 Australian secondary prevention guidelines (Reducing Risk in Heart Disease, 2012)
recommended an average daily intake of 1g of fish oils through either dietary or supplemental means, and only specifically recommended capsules/liquid for those with elevated triglycerides. 2 The AHA/ACCF Secondary Prevention Guidelines (2011) state it "may be reasonable" to recommend omega-3 fatty acids from fish or fish oil supplements. and all-cause mortality by 10% per mmol/L LDL cholesterol reduction. Amongst these endpoints the relative benefits of statin therapy were maintained across all levels of absolute cardiovascular risk. 10 Since patients with previous vascular disease have the highest absolute risks of recurrent cardiovascular events, they therefore stand to benefit the most from statin/more intensive treatment.
Potential adverse effects of statins include muscle conditions (ranging from myalgia to rhabdomyolysis), new onset type 2 diabetes mellitus, a very small increase in haemorrhagic stroke and transient reversible memory impairment. 12 Myalgia, by far the most common adverse effect, occurs in 1-5% of patients, whilst myopathy occurs in 0.1-0.5% and rhabdomyolysis in 0.01%. 12 Statin use has been associated with an increase in rate of diagnosis of incident diabetes by 9% in a meta-analysis of trials comparing statin to placebo, 13 and by 12% in a meta-analysis of trials comparing more vs. less intensive statin therapy. 14 This association is stronger in patients who are older and appears to be more common amongst patients with other risk factors for diabetes such as hypertension, higher BMI, higher baseline fasting glucose levels and higher triglycerides. 12 Despite the potential risk for new diabetes, which remains to be more definitively researched, the relative and absolute cardiovascular benefits from statin therapy vastly outweigh the risks associated with developing diabetes. 10 There have been post marketing surveillance reports of a possible rare association of statin treatment with mild cognitive impairment that appears to be reversible over a median time of 3 weeks after treatment withdrawal. No adverse link between statin treatment and dementia has been found despite some false media reports to the contrary. Randomised trials of statin therapy which specifically examined for cognitive changes did not identify any adverse effects. 12 Previous concerns about increases in cancer with statins have been convincingly refuted, at least within the median five year timeframe of 27 randomised trials. 10 In addition, there is now long term follow-up data from previous statin trial participants indicating no worse outcomes out to over 10 years for cancer incidence or death amongst those originally randomised to statin therapy compared to those allocated to placebo. 15 Current evidence strongly supports the use of statins in the secondary prevention of cardiovascular events, particularly as National Heart Foundation targets of LDL-C concentrations <1.8mmol/L for secondary prevention are difficult to achieve with lifestyle changes alone. 2 Adverse events are infrequent and serious events are extremely rare. Whilst there is debate regarding balancing absolute benefits against possible adverse events for low risk primary prevention, there should be no question about net benefit for secondary prevention, where the profound cardiovascular benefits of therapy firmly outweigh the risks.
Aspirin
An individual patient data meta-analysis by the Anti-thrombotic Trialists of 16 secondary prevention trials showed that aspirin reduced annual rates of serious vascular events (myocardial infarction, any stroke or vascular death) by 19%, major coronary events by 20%, any stroke by 19%, cardiovascular mortality by 9% and all-cause mortality by 10%. 16 Emerging data supports additional non-cardiovascular benefits of aspirin in reducing the 20-year risk of solid cancers (20%). 17 Haemorrhage is the main hazard of aspirin. The Antithrombotic Trialists calculated an increased risk of any major bleed with aspirin of 169%. Small absolute increases in haemorrhagic stroke are offset by much larger reductions in ischaemic stroke producing a net benefit with aspirin therapy, and no effect on fatal stroke. 16 Another meta-analysis of six secondary prevention trials using lower-dose (≤325mg) daily aspirin estimated an increased risk of gastrointestinal bleeds by 250%, representing an absolute increase from 0% to 2%
(+/-1.4%) over four years of follow up, with no deaths. 18 A comparison of the relative numbers needed to treat determined 1.5 deaths were prevented with aspirin for each GI bleed (of any severity) caused.
High-dose aspirin has not been shown to increase clinical benefits whilst definitely increasing the risk of bleeding complications. 19 Therefore in view of overwhelming evidence supporting the use of aspirin for secondary prevention of cardiovascular events, administering low-dose aspirin (75-150mg/day) will minimise the risk of adverse effects without compromising benefits.
ACE Inhibitors and Angiotensin Receptor Blockers
A large scale individual patient data meta-analysis of ~100000 pooled trial participants showed ACE inhibitors given in the acute phase (0-36h from symptom onset) of an MI significantly reduced 30 day mortality rates by 7%. 20 Another individual patient data metaanalysis pooling data from three long term trials amongst patients post MI with left ventricular dysfunction or clinical heart failure showed that ACE inhibitors reduced the risks of recurrent MI by 20%, readmission for heart failure by 27% and all-cause mortality by 26% over four years of follow-up. 21 Similar overall proportional benefits have been demonstrated in patients post MI with preserved ejection fractions.
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Trials comparing an angiotensin receptor blocker to an ACE inhibitor post MI with LV impairment have overall shown no difference in clinical benefits between the two classes in terms of reductions in MI, hospitalisation for heart failure, cardiovascular death and allcause mortality. 23, 24 In contrast to some evidence in chronic heart failure patients, no Overall, treatment with either an ACE inhibitor or ARB has clear evidence for cardiovascular event and mortality reductions after an acute coronary syndrome, irrespective of the presence of systolic ventricular impairment. There is no compelling evidence for combining them in this setting, which risks hyperkalaemia without added benefit.
Beta Blockers
Beta-blockers have longstanding evidence of efficacy in secondary prevention. A systematic review of nearly 25000 patients included in 31 long term randomised trials found betablockers reduce the risk of all-cause mortality by 23%. The number needed to treat over one year to prevent one death was 84 patients and to prevent one non-fatal cardiac reinfarction was 107. 26 Mortality benefits have also been established in populations in which underuse may be more common including patients aged ≥80, patients with COPD or diabetes, patients with resting heart rates <70 or systolic BP<100 and lower risk patients without any complications.
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A meta-regression analysis of 14 beta blockade trials found that reductions in cardiac death, sudden death and all-cause death as well as non-fatal MI were significantly related to the extent of heart rate reduction achieved. 28 However, a recent large randomised study investigating Ivabridine, a purely chronotropic agent, in patients with stable CAD found that despite significant heart rate reductions in the Ivabradine arm, the combined cardiovascular endpoint was not reduced, suggesting the cardiovascular benefits of beta blockers are not attributable solely to heart rate reductions. 29 In patients with heart failure from systolic dysfunction (due to any cause but including myocardial infarction) a systematic review and network meta-analysis showed beta-blockers reduced all-cause mortality by 29% without any significant difference shown between the long acting beta-blockers indicated for use in this setting. 30 The optimal long term duration of beta blockade therapy after MI is not currently known.
Registry data and observational studies suggest reductions in cardiovascular events may extend out to four years, with stronger evidence extending to six years in higher risk patients such as those with heart failure. 31, 32 In patients with normal left ventricular function, AHA/ACCF secondary prevention guidelines recommend beta-blocker therapy for at least three years and suggest ongoing treatment is reasonable (Class IIa, Level of evidence B). 9 Recently reported French registry data suggested there may be no additional mortality benefits from beta blockers beyond the first 12 months after an MI in patients with preserved systolic function (LVEF>40%), although likely confounding of this observational data has been raised as a major limitation in drawing strong conclusions. 33 Effects of beta-blockade which can prompt discontinuation include bradycardia and hypotension. Rarely other adverse events can require cessation such as fatigue (1.5%), depression (0.4%), reduced libido (0.2%), dizziness, vivid dreams and cold extremities. 26 Beta blockers have strong and longstanding evidence for cardiovascular event and mortality reductions in secondary prevention patients, particularly in patients with heart failure, noting there is some uncertainty about an ongoing benefit in patients with preserved systolic function beyond three years, and possibly sooner.
Clopidogrel / Other P2Y12 Antagonists (Ticagrelor, Prasugrel)
A systematic review and meta-analysis of randomised trials of dual antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention showed the addition of clopidogrel to aspirin reduced the risk of cardiovascular mortality by 7%, recurrent MI by 20% and stroke by 16% without any effect on the risk of intracranial haemorrhage. 34 Conflicting findings regarding bleeding risks have been reported. A recent meta-analysis amongst mostly secondary prevention trials reported a 40% increased relative risk of major bleeding using both clopidogrel and aspirin compared to aspirin alone, 35 while in other instances no increased risk was seen. 36 Loading doses likely contribute to bleeding risk -a higher loading dose of clopidogrel of 600mg (compared to 300mg) is recommended before percutaneous intervention in clopidogrel naïve patients due to improved cardiovascular outcomes, but this is at the expense of a higher major bleeding risk. 37 In recent years two additional P2Y12 inhibitors have emerged as potential alternatives to clopidogrel as a second antiplatelet agent: prasugrel and ticagrelor. Like clopidogrel, prasugrel is an irreversible thienopyridine P2Y12 inhibitor which is ingested as a pro-drug and metabolised by cytochrome P450 enzymes to its active form. It has a faster onset and greater degree of platelet inhibition than clopidogrel due to more efficient metabolism into its active form, and reduced function CYP polymorphisms do not appear to impact on prasugrel metabolism like they do up to 40% of patients who take clopidogrel. 38 In TRITON-TIMI 38, a randomised trial of 13600 people presenting with moderate-high risk ACS and scheduled for PCI, allocation to prasugrel compared to clopidogrel resulted in 19% fewer combined cardiovascular events, 24% fewer MIs and 52% fewer stent thromboses, with no effect on cardiovascular or all-cause mortality at 15 months follow-up. 39 This was at the expense of a 32% increase in non-CABG related TIMI major bleeding and a 473% increase in CABG related TIMI bleeding. Post-hoc subgroup analyses suggested that patients with a previous stroke or TIA were at a net risk of harm taking prasugrel, whilst those aged age≥75
or with body weight<60kg appeared to have a neutral outcome. As a consequence prasugrel is contraindicated in patients with a previous stroke or TIA and a lower dose is recommended for those aged ≥75 or with body weight <60kg.
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The TRILOGY-ACS trial compared prasugrel to clopidogrel in 7200 patients with either unstable angina or NSTEMI for medical management excluding patients with previous stroke/TIA. 41 Over 30 months of follow up there was no difference between prasugrel and clopidogrel in all cardiovascular, mortality and bleeding outcomes.
In terms of non-bleeding adverse events, hypersensitivity reactions are identified with all thienopyridines (clopidogrel and prasugrel). Clopidogrel reactions occur in about 1-2% of patients and mostly manifest within the first week of treatment as a diffuse erythematous progressively confluent rash. 42 Desensitisation can be attempted in mild cases. More severe outcomes including anaphylaxis are very rare. Substitution with another thienopyridine in the event of hypersensitivity is not recommended.
Ticagrelor is a directly acting reversible P2Y12 inhibitor which has both a more rapid onset of effect and achieves a greater level of platelet inhibition than clopidogrel. 43 In the PLATO trial which compared ticagrelor to clopidogrel in ACS patients, ticagrelor reduced the rates of the primary composite cardiovascular endpoint by 16%, myocardial infarction by 16%, stent thrombosis by 33%, cardiovascular death by 21% and all-cause mortality by 22%. 43 There was no difference in overall major bleeding events or fatal bleeding between the two treatments. Subgroup analyses have demonstrated similar net benefits irrespective of revascularization status, age (including those ≥75), diabetes, renal failure or previous TIA/stroke. 44 Ticagrelor can cause a non-pathological dyspnoea which is mostly a single self-limiting event early after treatment is commenced. It occurred in 5% more patients than clopidogrel in PLATO and 0.9% of patients discontinued treatment because of dyspnoea. 43 Patients reporting dyspnoea with ticagrelor had the same cardiovascular and mortality benefits as those without dyspnoea without evidence of altered pulmonary function. It is thought the mechanism for these symptoms may relate to increased extracellular adenosine levels from inhibition of adenosine reuptake. In PLATO ticagrelor also caused more ventricular pauses (≥3s) than clopidogrel (5.8% vs 3.6%) in the first week of treatment whilst a month later there were no differences between treatment groups. 43 Despite this there was no difference in the incidence of bradycardic adverse events, including syncope, pacemaker insertion or cardiac arrest. preference, noting that prasugrel is not recommended for UA/NSTEMI patients in whom conservative management is planned. 9 Australian secondary prevention guidelines make similar recommendations. 
Aldosterone Antagonists
Randomised controlled trials investigating aldosterone antagonists in patients with systolic heart failure have demonstrated significant reductions in all-cause mortality, driven by reductions in cardiovascular mortality, including sudden cardiac death. 46, 47 Hospitalisations for heart failure are also significantly reduced. Apart from reduced hospitalisations for heart failure, other cardiovascular benefits were not seen in a recently published study amongst patients with heart failure and a preserved ejection fraction. 48 recommend the use of either spironolactone or eplerenone in patients suffering from severe systolic heart failure of any aetiology (LVEF≤35% and NYHA class II-IV with some additional provisions for class II patients) or STEMI patients with LVEF≤40% on an ACE inhibitor and beta blocker and with heart failure signs or diabetes.
Of note all these trials excluded patients with hyperkalaemia (K≥5.0mmol/L) or moderate or worse renal impairment (eGFR<30mL/min/1.73m 2 or serum Cr>221µmol/L) due to the increased risk of hyperkalaemia with aldosterone antagonists, particularly in the presence of renal failure. Other endocrine side effects are possible including gynaecomastia, menstrual irregularities and increased libido. Eplerenone carries a much lower risk than spironolactone of these hormonal effects due to greater receptor specificity, but is more expensive.
Overall evidence supports prescription of aldosterone antagonists in secondary prevention patients with systolic heart failure, with significant mortality reductions. Renal function must be considered prior to prescription of either agent, whilst the endocrine side effect profile is more favourable for eplerenone than spironolactone.
Other Non-Pharmacological Interventions
Lifestyle interventions including smoking cessation, participation in exercise based cardiac rehabilitation, increased physical activity and avoiding excess alcohol consumption significantly reduce the risk of all-cause mortality. Annual influenza vaccination and dietary modification, particularly adopting a Mediterranean type diet, have both been showed to reduce major vascular events. Screening for depression is also important due to a strong association between depression and increased cardiovascular mortality after a myocardial infarction.
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Discussion
Whilst treatment prescription in medicine will always require an individualised approach there are notable ongoing deficiencies in the prescription of evidence based treatments for cardiovascular disease, in terms of overall rates and regional discrepancies. Mnemonics are frequently used in medicine to assist learning and rapid recall, and have the potential to aid clinicians in this regard. FFSAABC, a letter based mnemonic adopted over the last decade for treatments used in the secondary prevention of cardiovascular disease, has been reexamined in this review in light of updated evidence.
There is currently strong evidence to support the use of statins, aspirin, ACEI/ARBs, β- 
